Eventide Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Eventide Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-501,033	Closed	-$6.73M	–	160
2023 Q1	$6.73M	Sell	501,033 -298,967	-37%	-$5.17M	0.12%	126
2022 Q4	$9.9M	Hold	800,000	–	–	0.2%	107
2022 Q3	$11.2M	Hold	800,000	–	–	0.22%	102
2022 Q2	$11M	Hold	800,000	–	–	0.24%	94
2022 Q1	$13M	Buy	800,000 +472,556	+144%	+$7.4M	0.2%	103
2021 Q4	$5.33M	Buy	+327,444	New	+$5.52M	0.07%	131
2020 Q1	–	Sell	-100,000	Closed	-$12.4M	–	134
2019 Q4	$12.4M	Buy	+100,000	New	+$8.95M	0.35%	71
2019 Q2	–	Sell	-205,000	Closed	-$22.9M	–	135
2019 Q1	$22.9M	Buy	205,000 +37,000	+22%	+$4.04M	0.79%	47
2018 Q4	$16.9M	Buy	+168,000	New	+$17.4M	0.75%	49

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Eventide Asset Management's ICPT Position: Q2 2023 in Review

Eventide Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 501,033 shares — an estimated $6.73M sold.

Eventide Asset Management first reported a position in ICPT in Q4 2018 and held it in 9 quarters. The position peaked at $22.9M in Q1 2019. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Eventide Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Eventide Asset Management sold 501,033 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $6.73M.
Eventide Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2018 and held it in 9 quarters.
Eventide Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $22.9M in Q1 2019.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.